Aims: The FADS1/FADS2 gene cluster encodes Δ-5 and Δ-6 desaturase, rate-limiting enzymes in metabolism of linoleic (LA) to arachidonic (ARA) and α-linolenic to eicosapentaenoic and docosahexaenoic acid (DHA). Single nucleotide polymorphisms (SNPs) in FADS1/FADS2 contribute to variability in blood lipid fatty acids. Altered n–6 and n–3 fatty acids have been related to perinatal depression (PPD). Methods: We genotyped rs174553, rs99780, rs174575, and rs174583 in FADS1/FADS2, analyzed blood lipid fatty acids and assessed PPD risk as an Edinburgh Postnatal Depression Scale (EPDS) score ≧10 for 69 pregnant women. Results: 21, 12 and 15% women had an EPDS score ≧10 at 36 weeks’ gestation, 2 and 6 months postpartum, respectively. Quantitative trait analysis showed an association between rs174575 and PPD risk at 36 weeks’ gestation and 6 months postpartum. With haplotype ACCC (major alleles) for rs174553, rs99780, rs174575, rs174583, respectively, as reference, GTCT was positively associated with PPD risk at 36 weeks’ gestation, p = 0.028, and higher LA and lower ARA in plasma (p = 0.0001, p < 0.0001) and RBC ethanolamine phospholipids (p = 0.007, p = 0.005). Conclusions: We show that SNPs in FADS1/FADS2 are associated with higher blood lipid LA and lower ARA and PPD risk.

Keywords:
Fatty acid desaturase gene, Single nucleotide polymorphisms, Arachidonic acid, Eicosapentaenoic acid, Docosahexaenoic acid, Perinatal depression
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.